JP2014523516A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523516A5
JP2014523516A5 JP2014508165A JP2014508165A JP2014523516A5 JP 2014523516 A5 JP2014523516 A5 JP 2014523516A5 JP 2014508165 A JP2014508165 A JP 2014508165A JP 2014508165 A JP2014508165 A JP 2014508165A JP 2014523516 A5 JP2014523516 A5 JP 2014523516A5
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
pathway
hsp90
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014508165A
Other languages
English (en)
Japanese (ja)
Other versions
JP6363502B2 (ja
JP2014523516A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/035690 external-priority patent/WO2012149493A2/en
Publication of JP2014523516A publication Critical patent/JP2014523516A/ja
Publication of JP2014523516A5 publication Critical patent/JP2014523516A5/ja
Application granted granted Critical
Publication of JP6363502B2 publication Critical patent/JP6363502B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014508165A 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法 Expired - Fee Related JP6363502B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161480198P 2011-04-28 2011-04-28
US61/480,198 2011-04-28
PCT/US2012/035690 WO2012149493A2 (en) 2011-04-28 2012-04-27 Hsp90 combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016175431A Division JP6375345B2 (ja) 2011-04-28 2016-09-08 Ｈｓｐ９０併用療法

Publications (3)

Publication Number Publication Date
JP2014523516A JP2014523516A (ja) 2014-09-11
JP2014523516A5 true JP2014523516A5 (https=) 2015-06-18
JP6363502B2 JP6363502B2 (ja) 2018-07-25

Family

ID=47073116

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014508165A Expired - Fee Related JP6363502B2 (ja) 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法
JP2016175431A Expired - Fee Related JP6375345B2 (ja) 2011-04-28 2016-09-08 Ｈｓｐ９０併用療法
JP2018106047A Withdrawn JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016175431A Expired - Fee Related JP6375345B2 (ja) 2011-04-28 2016-09-08 Ｈｓｐ９０併用療法
JP2018106047A Withdrawn JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Country Status (12)

Country Link
US (2) US20140315929A1 (https=)
EP (1) EP2701747A4 (https=)
JP (3) JP6363502B2 (https=)
KR (2) KR102027448B1 (https=)
CN (2) CN103998935B (https=)
AU (3) AU2012249322B2 (https=)
BR (1) BR112013027448A2 (https=)
CA (1) CA2833390A1 (https=)
EA (1) EA201391587A1 (https=)
MX (1) MX2013012183A (https=)
NZ (1) NZ618062A (https=)
WO (1) WO2012149493A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2729806T3 (en) 2011-07-08 2017-05-15 Sloan-Kettering Inst For Cancer Res APPLICATIONS OF MARKED HSP90 INHIBITORS
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
UA118548C2 (uk) 2012-12-21 2019-02-11 Епізайм, Інк. Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування
US10071130B2 (en) 2013-12-12 2018-09-11 The University Of Chicago Methods and compositions related to Hsp90 inhibitors and breast cancer
MX2016008418A (es) 2013-12-23 2017-01-11 Memorial Sloan Kettering Cancer Center Metodos y reactivos para el radiomarcaje.
MX2016014365A (es) * 2014-05-02 2017-04-27 Wistar Inst Terapias combinadas dirigidas a mitocondrias para la terapia contra cancer.
CN113521314A (zh) 2014-09-17 2021-10-22 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
AU2015335907A1 (en) 2014-10-21 2017-04-13 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
WO2016168344A1 (en) * 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived characterization, diaganostics and therapeutics for conditions associated with functional features
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
CN106265660B (zh) * 2015-05-21 2019-08-02 中国科学院合肥物质科学研究院 A674563在携带flt3突变型基因的急性白血病中的用途
CN106349180B (zh) * 2015-07-14 2020-05-19 上海翰森生物医药科技有限公司 4,5-二苯基异噁唑衍生物及其制备方法和应用
AU2017305502B2 (en) * 2016-08-03 2024-06-20 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
WO2018144680A1 (en) * 2017-02-03 2018-08-09 Lam Therapeutics, Inc. Methods for treating cancer using hsp90 inhibitors
CN110799194A (zh) 2017-06-20 2020-02-14 马德里加尔制药公司 包含靶向治疗剂的联合疗法
EP3641647A4 (en) 2017-06-20 2021-05-05 Madrigal Pharmaceuticals, Inc. TARGETED THERAPEUTICS
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
CN109554343B (zh) * 2018-12-29 2022-04-19 吉林大学 一种适于神经元粘附与存活的涂层材料及制备方法
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
CN111467472B (zh) * 2020-04-21 2020-12-25 南京中医药大学 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用
US20230218577A1 (en) * 2020-06-11 2023-07-13 The Children's Medical Center Corporation Use of heat shock protein inhibitors for the treatment of neurodevelopmental disorders
CA3191819A1 (en) 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria
KR20230088763A (ko) * 2020-10-14 2023-06-20 라녹 테라퓨틱스 (항저우) 컴퍼니, 리미티드 표적 단백질 분해를 위한 방법 및 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
WO2009018233A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
US20070105874A1 (en) 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
EP2073802A1 (en) * 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
BRPI0807812A2 (pt) * 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
WO2008114812A1 (ja) * 2007-03-19 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Jak阻害剤
WO2009073575A2 (en) * 2007-11-30 2009-06-11 Oregon Health & Science University Methods for treating induced cellular proliferative disorders
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP2012500013A (ja) * 2008-08-18 2012-01-05 マックス−プランク−ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー．ファウ． Ｈｓｐ９０阻害剤に対する感受性
CN105727297A (zh) * 2008-11-28 2016-07-06 诺华股份有限公司 包含hsp90抑制剂和mtor抑制剂的药物组合
US8669289B2 (en) * 2009-04-24 2014-03-11 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
WO2010147898A2 (en) * 2009-06-15 2010-12-23 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
KR101906146B1 (ko) * 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
CN107898791A (zh) * 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
WO2012162372A1 (en) * 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors

Similar Documents

Publication Publication Date Title
JP2014523516A5 (https=)
Bruix et al. Insights into the success and failure of systemic therapy for hepatocellular carcinoma
Fisher et al. Cancer heterogeneity: implications for targeted therapeutics
Johnson et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Remon et al. The APPLE trial: feasibility and activity of AZD9291 (osimertinib) treatment on positive plasma T790M in EGFR-mutant NSCLC patients. EORTC 1613
Roberts et al. KRAS mutation: should we test for it, and does it matter?
Douillard et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status
Bissolati et al. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer
Patel et al. Next-generation sequencing: a novel approach to distinguish multifocal primary lung adenocarcinomas from intrapulmonary metastases
Mezentsev et al. Global gene expression responses to low-or high-dose radiation in a human three-dimensional tissue model
Peng et al. Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA
Okines et al. Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
Dietel Molecular pathology: a requirement for precision medicine in cancer
Kamran et al. Applying precision oncology principles in radiation oncology
Gerger et al. Molecular predictors of response to antiangiogenesis therapies
Stahel et al. Strategies for improving outcomes in NSCLC: a look to the future
Li et al. Prognostic significance of BCL-2 and BCL-6 expression in MYC-positive DLBCL
Grinspan et al. Biomarker development using liquid biopsy in hepatocellular carcinoma
Lee et al. Large cell neuroendocrine carcinoma transformation as a mechanism of acquired resistance to osimertinib in non-small cell lung cancer: case report and literature review
Kang et al. A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
Shen et al. Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer
Torricelli et al. Genomic analysis in short-and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy
Ito et al. Clinicopathological and molecular characteristics promoting PD-L1 expression in early-stage lung adenocarcinoma and squamous cell carcinoma
Pu et al. Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: biological and clinical implications
Benderra et al. Acquired EGFR mutation as the potential resistance driver to crizotinib in a MET-mutated tumor